Prediction of Chemotherapy-Induced Peripheral Neuropathy in Patients with Lymphoma and Myeloma: the Roles of Brain-Derived Neurotropic Factor Protein Levels and A Gene Polymorphism
Open Access
- 1 January 2019
- journal article
- research article
- Published by XMLink in Journal of Clinical Neurology
- Vol. 15 (4) , 511-516
Abstract
No abstract availableKeywords
Funding Information
- Israel Cancer Research Fund
This publication has 27 references indexed in Scilit:
- Association between Met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathyBreast Cancer Research and Treatment, 2015
- Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysisPain, 2014
- BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's diseaseNeuroscience Letters, 2014
- Release reaction of brain-derived neurotrophic factor (BDNF) through PAR1 activation and its two distinct pools in human plateletsThrombosis Research, 2011
- The role of BDNF in depression on the basis of its location in the neural circuitryActa Pharmacologica Sinica, 2010
- Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depressionNeurobiology of Aging, 2009
- A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depressionInternational Journal of Neuropsychopharmacology, 2008
- Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotectionJournal of Neuroimmunology, 2008
- Screening for Depression in Medical Settings with the Patient Health Questionnaire (PHQ): A Diagnostic Meta-AnalysisJournal of General Internal Medicine, 2007
- Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetateJournal of Neuroimmunology, 2005